Thalidomide after allogeneic haematopoietic stem cell transplantation: Activity in chronic but not in acute graft-versus-host disease

S. Kulkarni, R. Powles*, B. Sirohi, J. Treleaven, R. Saso, C. Horton, A. Atra, M. Ortin, C. Rudin, S. Goyal, S. Sankpal, S. Meller, C. R. Pinkerton, J. Mehta, S. Singhal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Thalidomide was used to treat acute (n = 21) or chronic (n = 59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and corticosteroids with or without other agents. The median time to onset of acute GVHD was 11 days, and thalidomide was started at a median of 48 days post transplant. In addition to corticosteroids and cyclosporine, 13 patients had also received other agents before thalidomide. None of the patients responded and all died of acute GVHD. For chronic GVHD (limited in 13, extensive in 46), thalidomide was started at a median of 385 days post transplant. In addition to corticosteroids and cyclosporine, 34 patients received azathioprine concomitantly. In all patients, thalidomide was added to the ongoing immunosuppressive regimen. The median duration of therapy with thalidomide was 60 days (range, 11-1210; <2 weeks in 11). In total, 13 patients (22%) had complete response, eight (14%) partial response and 38 (64%) no response. Response rates were comparable for limited (39%) and extensive (33%) chronic GVHD. At a median of 53 months, 19 patients are alive, 13 without evidence of chronic GVHD. Survival was significantly better in patients who responded to thalidomide. The principal causes of death were progressive chronic GVHD (n = 29) and relapsed leukaemia (n = 7). In conclusion, thalidomide has no activity in acute GVHD, but has some activity in chronic GVHD in combination with other agents.

Original languageEnglish (US)
Pages (from-to)165-170
Number of pages6
JournalBone Marrow Transplantation
Volume32
Issue number2
DOIs
StatePublished - Jul 2003

Keywords

  • GVHD
  • Thalidomide
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Thalidomide after allogeneic haematopoietic stem cell transplantation: Activity in chronic but not in acute graft-versus-host disease'. Together they form a unique fingerprint.

Cite this